David R Jones

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3984367/publications.pdf Version: 2024-02-01



DAVID P IONES

#	Article	IF	CITATIONS
1	The American College of Surgeons Surgical Risk Calculator performs well for pulmonary resection: AÂvalidation study. Journal of Thoracic and Cardiovascular Surgery, 2022, 163, 1509-1516.e1.	0.4	6
2	Challenges to Randomized Trials in Adult and Congenital Cardiac and Thoracic Surgery. Annals of Thoracic Surgery, 2022, 113, 1409-1418.	0.7	8
3	Shape-Sensing Robotic-Assisted Bronchoscopy in the Diagnosis of Pulmonary Parenchymal Lesions. Chest, 2022, 161, 572-582.	0.4	82
4	A More Extensive Lymphadenectomy Enhances Survival After Neoadjuvant Chemoradiotherapy in Locally Advanced Esophageal Adenocarcinoma. Annals of Surgery, 2022, 276, 312-317.	2.1	13
5	Tumor and Tumor-Associated Macrophage Programmed Death-Ligand 1 Expression Is Associated With Adjuvant Chemotherapy Benefit in Lung Adenocarcinoma. Journal of Thoracic Oncology, 2022, 17, 89-102.	0.5	16
6	Survival After Trimodality Therapy in Patients With Locally Advanced Esophagogastric Adenocarcinoma. Annals of Surgery, 2022, 276, 1017-1022.	2.1	10
7	Genomic characterization of metastatic patterns from prospective clinical sequencing of 25,000 patients. Cell, 2022, 185, 563-575.e11.	13.5	223
8	Defining and Targeting Esophagogastric Cancer Genomic Subsets With Patient-Derived Xenografts. JCO Precision Oncology, 2022, 6, e2100242.	1.5	5
9	Impact of Tumor Mutational Burden and Gene Alterations Associated with Radiation-Response on Outcomes of Post-Operative Radiation Therapy in Non-Small Cell Lung Cancer. International Journal of Radiation Oncology Biology Physics, 2022, , .	0.4	8
10	Patterns and influence of nodal metastases after neoadjuvant chemoradiation and RO resection in esophageal adenocarcinoma. Journal of Thoracic and Cardiovascular Surgery, 2022, 164, 411-419.	0.4	4
11	CT-based Radiogenomic Analysis of Clinical Stage I Lung Adenocarcinoma with Histopathologic Features and Oncologic Outcomes. Radiology, 2022, 303, 664-672.	3.6	28
12	Amiodarone with or without <i>N</i> -Acetylcysteine for the Prevention of Atrial Fibrillation after Thoracic Surgery: A Double-blind, Randomized Trial. Anesthesiology, 2022, 136, 916-926.	1.3	10
13	The Role of the TP53 Pathway in Predicting Response to Neoadjuvant Therapy in Esophageal Adenocarcinoma. Clinical Cancer Research, 2022, 28, 2669-2678.	3.2	6
14	Postinduction therapy pulmonary function retesting is necessary before surgical resection for non–small cell lung cancer. Journal of Thoracic and Cardiovascular Surgery, 2022, 164, 389-397.e7.	0.4	2
15	Early implementation of a perioperative nutrition support pathway for patients undergoing esophagectomy for esophageal cancer. Cancer Medicine, 2022, 11, 592-601.	1.3	4
16	Phase II Trial Evaluating Esophageal Anastomotic Reinforcement with a Biologic, Degradable, Extracellular Matrix after Total Gastrectomy and Esophagectomy. Journal of the American College of Surgeons, 2022, 234, 910-917.	0.2	1
17	How to maximize the bandwidth without increasing the noise in op-amp-based transimpedance amplifiers using positive feedback. Review of Scientific Instruments, 2022, 93, 043004.	0.6	2
18	Germline Pathogenic Variants Impact Clinicopathology of Advanced Lung Cancer. Cancer Epidemiology Biomarkers and Prevention, 2022, 31, 1450-1459.	1.1	10

#	Article	IF	CITATIONS
19	Survival and Scoliosis Following Resection of Chest Wall Tumors in Children and Adolescents. Annals of Surgery, 2021, 274, e167-e173.	2.1	12
20	Two-Year Quality of Life Outcomes After Robotic-Assisted Minimally Invasive and Open Esophagectomy. Annals of Thoracic Surgery, 2021, 112, 880-889.	0.7	13
21	External Validation of Surgical Risk Preoperative Assessment System in Pulmonary Resection. Annals of Thoracic Surgery, 2021, 112, 228-237.	0.7	5
22	Intentional Segmentectomy for Clinical T1 N0 Non-small Cell Lung Cancer: Survival Differs by Segment. Annals of Thoracic Surgery, 2021, 111, 1028-1035.	0.7	10
23	Predictors of survival following surgical resection of limited-stage small cell lung cancer. Journal of Thoracic and Cardiovascular Surgery, 2021, 161, 760-771.e2.	0.4	23
24	Safety and feasibility of esophagectomy following combined immunotherapy and chemoradiotherapy for esophageal cancer. Journal of Thoracic and Cardiovascular Surgery, 2021, 161, 836-843.e1.	0.4	62
25	Performance Comparison Between SURPAS and ACS NSQIP Surgical Risk Calculator in Pulmonary Resection. Annals of Thoracic Surgery, 2021, 111, 1643-1651.	0.7	7
26	Use of vasopressors during esophagectomy is not associated with increased risk of anastomotic leak. Ecological Management and Restoration, 2021, 34, .	0.2	7
27	How Effective Is Neoadjuvant Therapy Followed by Surgery for Pathologic Single-Station N2 Non–Small Cell Lung Cancer?. Seminars in Thoracic and Cardiovascular Surgery, 2021, 33, 206-216.	0.4	6
28	<i>KRAS</i> G12C Mutation Is Associated with Increased Risk of Recurrence in Surgically Resected Lung Adenocarcinoma. Clinical Cancer Research, 2021, 27, 2604-2612.	3.2	20
29	A Genomic-Pathologic Annotated Risk Model to Predict Recurrence in Early-Stage Lung Adenocarcinoma. JAMA Surgery, 2021, 156, e205601.	2.2	52
30	Canyons and Volcanoes: The Effects of Radiation on the Chest Wall. Annals of Thoracic Surgery, 2021, 112, e415-e418.	0.7	2
31	Oligometastases After Curative Esophagectomy Are Not One Size Fits All. Annals of Thoracic Surgery, 2021, 112, 1775-1781.	0.7	9
32	Extracellular vesicle and particle isolation from human and murine cell lines, tissues, and bodily fluids. STAR Protocols, 2021, 2, 100225.	0.5	15
33	Management of Synchronous Extrathoracic Oligometastatic Non-Small Cell Lung Cancer. Cancers, 2021, 13, 1893.	1.7	10
34	Thoracic Metastasectomy in Germ Cell Tumor Patients Treated With First-line Versus Salvage Therapy. Annals of Thoracic Surgery, 2021, 111, 1141-1149.	0.7	4
35	Next-Generation Sequencing of 487 Esophageal Adenocarcinomas Reveals Independently Prognostic Genomic Driver Alterations and Pathways. Clinical Cancer Research, 2021, 27, 3491-3498.	3.2	8
36	Diaphragm hernia after debulking surgery in patients with ovarian cancer. Gynecologic Oncology Reports, 2021, 36, 100759.	0.3	2

#	Article	IF	CITATIONS
37	Thoracoscopic lobectomy following neoadjuvant tyrosine kinase inhibitor treatment. JTCVS Techniques, 2021, 7, 294-297.	0.2	4
38	Targeted therapies for resectable lung adenocarcinoma: ADAURA opens for thoracic oncologic surgeons. Journal of Thoracic and Cardiovascular Surgery, 2021, 162, 288-292.	0.4	7
39	Prevalence of Germline Alterations on Targeted Tumor-Normal Sequencing of Esophagogastric Cancer. JAMA Network Open, 2021, 4, e2114753.	2.8	15
40	Neoadjuvant immunochemotherapy in surgically resectable non-small-cell lung cancer: surgical expertise required. European Journal of Cardio-thoracic Surgery, 2021, 60, 88-90.	0.6	2
41	Preoperative clinical and tumor genomic features associated with pathologic lymph node metastasis in clinical stage I and II lung adenocarcinoma. Npj Precision Oncology, 2021, 5, 70.	2.3	8
42	Intraoperative opioid exposure, tumour genomic alterations, and survival differences in people with lung adenocarcinoma. British Journal of Anaesthesia, 2021, 127, 75-84.	1.5	33
43	The Emerging Importance of Tumor Genomics in Operable Non-Small Cell Lung Cancer. Cancers, 2021, 13, 3656.	1.7	8
44	Transcriptional programs of neoantigen-specific TIL in anti-PD-1-treated lung cancers. Nature, 2021, 596, 126-132.	13.7	234
45	A Phase I Trial of Regional Mesothelin-Targeted CAR T-cell Therapy in Patients with Malignant Pleural Disease, in Combination with the Anti–PD-1 Agent Pembrolizumab. Cancer Discovery, 2021, 11, 2748-2763.	7.7	222
46	A nutritional management algorithm in older patients with locally advanced esophageal cancer. Journal of Geriatric Oncology, 2021, , .	0.5	2
47	Understanding adverse events related to perioperative immunotherapy: A primer for thoracic surgeons. Thoracic Cancer, 2021, 12, 2291-2292.	0.8	0
48	Spread Through Air Spaces (STAS) in Nonâ^'Small Cell Lung Carcinoma. American Journal of Surgical Pathology, 2021, 45, 1509-1515.	2.1	14
49	Modification of Pathologic T Classification for Non-small Cell Lung Cancer With Visceral Pleural Invasion. Chest, 2021, 160, 754-764.	0.4	13
50	Intraoperative ketorolac may interact with patient-specific tumour genomics to modify recurrence risk in lung adenocarcinoma: an exploratory analysis. British Journal of Anaesthesia, 2021, 127, e82-e85.	1.5	5
51	Clinical utility of next-generation sequencing-based ctDNA testing for common and novel ALK fusions. Lung Cancer, 2021, 159, 66-73.	0.9	17
52	Treatment of anastomotic recurrence after esophagectomy. Annals of Thoracic Surgery, 2021, , .	0.7	4
53	Defining low-risk lesions in early-stage esophageal adenocarcinoma. Journal of Thoracic and Cardiovascular Surgery, 2021, 162, 1272-1279.	0.4	3
54	Outcomes After Multidisciplinary Management of Primary Mediastinal Germ Cell Tumors. Annals of Surgery, 2021, 274, e1099-e1107.	2.1	9

#	Article	IF	CITATIONS
55	Primary lung cancer in women after previous breast cancer. BJS Open, 2021, 5, .	0.7	6
56	Signatures of plasticity, metastasis, and immunosuppression in an atlas of human small cell lung cancer. Cancer Cell, 2021, 39, 1479-1496.e18.	7.7	155
57	Uniportal video-assisted thoracoscopic surgery (UniVATS) left upper lobectomy in 9 steps. JTCVS Techniques, 2021, 10, 483-488.	0.2	0
58	Long-term assessment of efficacy with a novel Thoracic Survivorship Program for patients with lung cancer. Journal of Thoracic and Cardiovascular Surgery, 2021, , .	0.4	5
59	Higher clinical suspicion is needed for prompt diagnosis of esophageal adenocarcinoma in young patients. Journal of Thoracic and Cardiovascular Surgery, 2020, 159, 317-326.e5.	0.4	5
60	Prevalence of Occult Peribronchial N1 Nodal Metastasis in Peripheral Clinical N0 Small (â‰ 2 cm) Non-Small Cell Lung Cancer. Annals of Thoracic Surgery, 2020, 109, 270-276.	0.7	24
61	Incidence and Risk Factors for Isolated Esophageal Cancer Recurrence to the Brain. Annals of Thoracic Surgery, 2020, 109, 329-336.	0.7	20
62	Long-term, disease-specific outcomes of thymic malignancies presenting with de novo pleural metastasis. Journal of Thoracic and Cardiovascular Surgery, 2020, 159, 705-714.e1.	0.4	18
63	Decreasing use of epidural analgesia with increasing minimally invasive lobectomy: Impact on postoperative morbidity. Lung Cancer, 2020, 139, 68-72.	0.9	11
64	Unique Considerations for Females Undergoing Esophagectomy. Annals of Surgery, 2020, 272, 113-117.	2.1	13
65	SMARCA4-Deficient Thoracic Sarcomatoid Tumors Represent Primarily Smoking-Related Undifferentiated Carcinomas Rather Than Primary Thoracic Sarcomas. Journal of Thoracic Oncology, 2020, 15, 231-247.	0.5	172
66	Video-assisted thoracic surgery in the primary management of advanced ovarian carcinoma with moderate to large pleural effusions: A Memorial Sloan Kettering Cancer Center Team Ovary Study. Gynecologic Oncology, 2020, 159, 66-71.	0.6	12
67	Preface. General Thoracic and Cardiovascular Surgery, 2020, 68, 659-659.	0.4	0
68	Response to the Letter to the Editor: Clinical and Pathologic Implications of Tumor Genomics of Predominant Histologic Subtypes in Lung Adenocarcinoma. Journal of Thoracic Oncology, 2020, 15, e188-e189.	0.5	0
69	Extracellular Vesicle and Particle Biomarkers Define Multiple Human Cancers. Cell, 2020, 182, 1044-1061.e18.	13.5	691
70	The Underlying Tumor Genomics of Predominant Histologic Subtypes in Lung Adenocarcinoma. Journal of Thoracic Oncology, 2020, 15, 1844-1856.	0.5	83
71	Neoadjuvant nivolumab plus ipilimumab in resectable non-small cell lung cancer. , 2020, 8, e001282.		108
72	Is Routine Chest Radiography Necessary After Endobronchial Ultrasound–guided Fine Needle Aspiration?. Annals of Thoracic Surgery, 2020, 112, 467-472.	0.7	0

#	Article	IF	CITATIONS
73	American Association for Thoracic Surgery: Maintaining the mission during the coronavirus disease 2019 (COVID-19) pandemic. Journal of Thoracic and Cardiovascular Surgery, 2020, 160, 737-739.	0.4	7
74	Time-varying analysis of readmission and mortality during the first year after pneumonectomy. Journal of Thoracic and Cardiovascular Surgery, 2020, 160, 247-255.e5.	0.4	11
75	A prospective trial of intraoperative tissue oxygenation measurement and its association with anastomotic leak rate after lvor Lewis esophagectomy. Journal of Thoracic Disease, 2020, 12, 1449-1459.	0.6	2
76	Prognostic factors following complete resection of non-superior sulcus lung cancer invading the chest wall. European Journal of Cardio-thoracic Surgery, 2020, 58, 78-85.	0.6	10
77	Tumor Spread Through Air Spaces Is a Predictor of Occult Lymph Node Metastasis in Clinical Stage IA Lung Adenocarcinoma. Journal of Thoracic Oncology, 2020, 15, 792-802.	0.5	43
78	A Stepwise Approach for Postlobectomy Bronchopleural Fistula. Operative Techniques in Thoracic and Cardiovascular Surgery, 2020, 25, 85-104.	0.2	5
79	Compartmental Analysis of T-cell Clonal Dynamics as a Function of Pathologic Response to Neoadjuvant PD-1 Blockade in Resectable Non–Small Cell Lung Cancer. Clinical Cancer Research, 2020, 26, 1327-1337.	3.2	90
80	COVID-19 Guidance for Triage of Operations for Thoracic Malignancies: AÂConsensus Statement From Thoracic Surgery Outcomes Research Network. Annals of Thoracic Surgery, 2020, 110, 692-696.	0.7	72
81	COVID-19 guidance for triage of operations for thoracic malignancies: A consensus statement from Thoracic Surgery Outcomes Research Network. Journal of Thoracic and Cardiovascular Surgery, 2020, 160, 601-605.	0.4	52
82	HER2-Mediated Internalization of Cytotoxic Agents in <i>ERBB2</i> Amplified or Mutant Lung Cancers. Cancer Discovery, 2020, 10, 674-687.	7.7	149
83	MYBL2-Driven Transcriptional Programs Link Replication Stress and Error-prone DNA Repair With Genomic Instability in Lung Adenocarcinoma. Frontiers in Oncology, 2020, 10, 585551.	1.3	7
84	Propensity-matched Analysis Demonstrates Long-term Risk of Respiratory and Cardiac Mortality After Pneumonectomy Compared With Lobectomy for Lung Cancer. Annals of Surgery, 2020, Publish Ahead of Print, .	2.1	4
85	Does Induction Immunotherapy Confer Increased Operative Risk for Lung Resection?. Difficult Decisions in Surgery: an Evidence-based Approach, 2020, , 205-214.	0.0	0
86	Complex chest wall surgery to prevent vascular complications after immunotherapy and radiation treatment. JTCVS Techniques, 2020, 4, 329-331.	0.2	2
87	Survival Following Trimodality Therapy in Patients With Locally Advanced Esophagogastric Adenocarcinoma: Does Only a Complete Pathologic Response Matter?. Annals of Surgery, 2020, , .	2.1	5
88	Tumour exosomal CEMIP protein promotes cancer cell colonization in brain metastasis. Nature Cell Biology, 2019, 21, 1403-1412.	4.6	254
89	Comprehensive Next-Generation Sequencing Unambiguously Distinguishes Separate Primary Lung Carcinomas From Intrapulmonary Metastases: Comparison with Standard Histopathologic Approach. Clinical Cancer Research, 2019, 25, 7113-7125.	3.2	69
90	Frequency and outcomes of brain metastases in patients with <i>HER2</i> â€mutant lung cancers. Cancer, 2019, 125, 4380-4387.	2.0	51

#	Article	IF	CITATIONS
91	Analysis of Tumor Genomic Pathway Alterations Using Broad-Panel Next-Generation Sequencing in Surgically Resected Lung Adenocarcinoma. Clinical Cancer Research, 2019, 25, 7475-7484.	3.2	30
92	Early Quality of Life Outcomes After Robotic-Assisted Minimally Invasive and Open Esophagectomy. Annals of Thoracic Surgery, 2019, 108, 920-928.	0.7	54
93	Surveillance Implications of Recurrence Patterns in Early Node-Negative Esophageal Adenocarcinoma. Annals of Thoracic Surgery, 2019, 108, 1640-1647.	0.7	15
94	Patterns and risk of recurrence in patients with esophageal cancer with a pathologic complete response after chemoradiotherapy followed by surgery. Journal of Thoracic and Cardiovascular Surgery, 2019, 157, 1249-1259.e5.	0.4	47
95	Enhanced bandwidth, high gain, low noise transimpedance amplifier for asynchronous optical sampling systems. Review of Scientific Instruments, 2019, 90, 063103.	0.6	4
96	Cyclic compression increases F508 Del CFTR expression in ciliated human airway epithelium. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2019, 317, L247-L258.	1.3	6
97	Ongoing Challenges with Clinical Assessment of Nodal Status in T1 Esophageal Adenocarcinoma. Journal of the American College of Surgeons, 2019, 229, 366-373.	0.2	8
98	NF-κB upregulates glutamine-fructose-6-phosphate transaminase 2 to promote migration in non-small cell lung cancer. Cell Communication and Signaling, 2019, 17, 24.	2.7	33
99	A brain natriuretic peptide-based prediction model for atrial fibrillation after thoracic surgery: Development and internal validation. Journal of Thoracic and Cardiovascular Surgery, 2019, 157, 2493-2499.e1.	0.4	32
100	Perioperative blood transfusion has a dose-dependent relationship with disease recurrence and survival in patients with non–small cell lung cancer. Journal of Thoracic and Cardiovascular Surgery, 2019, 157, 2469-2477.e10.	0.4	32
101	Incorporating Innovation and New Technology Into Cardiothoracic Surgery. Annals of Thoracic Surgery, 2019, 107, 1267-1274.	0.7	10
102	Initial results of pulmonary resection after neoadjuvant nivolumab in patients with resectable non–small cell lung cancer. Journal of Thoracic and Cardiovascular Surgery, 2019, 158, 269-276.	0.4	218
103	American Board of Thoracic Surgery 10-Year Maintenance of Certification Exam Improves and Validates Knowledge Acquisition. Annals of Thoracic Surgery, 2019, 108, 1895-1900.	0.7	2
104	Outcomes of Radiation-Associated Esophageal Squamous Cell Carcinoma: The MSKCC Experience. Journal of Gastrointestinal Surgery, 2019, 23, 11-22.	0.9	5
105	Does pyloric drainage have a role in the era of minimally invasive esophagectomy?. Surgical Endoscopy and Other Interventional Techniques, 2019, 33, 3218-3227.	1.3	17
106	Outcomes of Stage III NSCLC with occult primary vs. known primary lesions. Lung Cancer, 2019, 127, 34-36.	0.9	2
107	Pathologic Assessment After Neoadjuvant Chemotherapy for NSCLC: Importance and Implications of Distinguishing Adenocarcinoma From Squamous Cell Carcinoma. Journal of Thoracic Oncology, 2019, 14, 482-493.	0.5	81
108	Outcomes after neoadjuvant or adjuvant chemotherapy for cT2-4N0-1 non–small cell lung cancer: A propensity-matched analysis. Journal of Thoracic and Cardiovascular Surgery, 2019, 157, 743-753.e3.	0.4	30

#	Article	IF	CITATIONS
109	Procedure-Specific Risk Prediction for Recurrence in Patients Undergoing Lobectomy or Sublobar Resection for Small (â‰ û cm) Lung Adenocarcinoma: An International Cohort Analysis. Journal of Thoracic Oncology, 2019, 14, 72-86.	0.5	41
110	Lobectomy Is Associated with Better Outcomes than Sublobar Resection in Spread through Air Spaces (STAS)-Positive T1 Lung Adenocarcinoma: AÂPropensity Score–Matched Analysis. Journal of Thoracic Oncology, 2019, 14, 87-98.	0.5	153
111	A systematic review and meta-analysis of stereotactic body radiation therapy versus surgery for patients with non–small cell lung cancer. Journal of Thoracic and Cardiovascular Surgery, 2019, 157, 362-373.e8.	0.4	57
112	Multimodality Therapy for N2 Non-Small Cell Lung Cancer: An Evolving Paradigm. Annals of Thoracic Surgery, 2019, 107, 277-284.	0.7	17
113	A Prospective Study of Circulating Tumor DNA to Guide Matched Targeted Therapy in Lung Cancers. Journal of the National Cancer Institute, 2019, 111, 575-583.	3.0	96
114	Minimally Invasive Lobectomy Is Associated With Lower Noncancer-specific Mortality in Elderly Patients. Annals of Surgery, 2019, 270, 1161-1169.	2.1	27
115	Frontal lobe ¹ H MR spectroscopy in asymptomatic and symptomatic <i>MAPT</i> mutation carriers. Neurology, 2019, 93, e758-e765.	1.5	18
116	Stereotactic ablative radiotherapy for operable stage I non-small cell lung cancer: not ready for prime time. Annals of Translational Medicine, 2019, 7, S234-S234.	0.7	2
117	Neoadjuvant PD-1 Blockade in Resectable Lung Cancer. New England Journal of Medicine, 2018, 378, 1976-1986.	13.9	1,495
118	Bending the Curve: The Importance ofÂExpertise. Annals of Thoracic Surgery, 2018, 105, 1287-1293.	0.7	4
119	Circulating tumor DNA: A promising biomarker to guide postoperative treatment and surveillance of non–small cell lung cancer. Journal of Thoracic and Cardiovascular Surgery, 2018, 155, 2628-2631.	0.4	10
120	Quality of Endoscopy Reports for Esophageal Cancer Patients: Where Do We Stand?. Journal of Gastrointestinal Surgery, 2018, 22, 778-784.	0.9	4
121	Predictors of Nodal Metastases for Clinical T2NO Esophageal Adenocarcinoma. Annals of Thoracic Surgery, 2018, 106, 172-177.	0.7	13
122	Catheter-based endobronchial electroporation is feasible for the focal treatment of peribronchial tumors. Journal of Thoracic and Cardiovascular Surgery, 2018, 155, 2150-2159.e3.	0.4	13
123	Factors associated with distant recurrence following R0 lobectomy for pN0 lung adenocarcinoma. Journal of Thoracic and Cardiovascular Surgery, 2018, 155, 1212-1224.e3.	0.4	23
124	Safety and Feasibility of Lung Resection After Immunotherapy for Metastatic or Unresectable Tumors. Annals of Thoracic Surgery, 2018, 106, 178-183.	0.7	96
125	Feasibility of endobronchial ultrasound transbronchial needle aspiration for massively parallel next-generation sequencing in thoracic cancer patients. Lung Cancer, 2018, 119, 85-90.	0.9	38
126	Definitive chemoradiotherapy versus neoadjuvant chemoradiotherapy followed by surgery for stage II to III esophageal squamous cell carcinoma. Journal of Thoracic and Cardiovascular Surgery, 2018, 155, 2710-2721.e3.	0.4	41

#	Article	IF	CITATIONS
127	Preponderance of High-Grade Histologic Subtype in Autologous Metastases in Lung Adenocarcinoma. American Journal of Respiratory and Critical Care Medicine, 2018, 197, 816-818.	2.5	7
128	BRMS1 Expression in Surgically Resected Lung Adenocarcinoma Predicts Future Metastases and IsÂAssociated with a Poor Prognosis. Journal of Thoracic Oncology, 2018, 13, 73-84.	0.5	17
129	Genetic Predictors of Response to Systemic Therapy in Esophagogastric Cancer. Cancer Discovery, 2018, 8, 49-58.	7.7	275
130	Stereotactic Body Radiation Therapy: Focusing on the Short Game. Journal of Clinical Oncology, 2018, 36, 2455-2456.	0.8	3
131	More Frequent Surveillance Following Lung Cancer Resection Is Not Associated With Improved Survival. Annals of Surgery, 2018, 268, 632-639.	2.1	29
132	Sentinel lymph node mapping in lung cancer: a step forward?. Journal of Thoracic Disease, 2018, 10, S3254-S3256.	0.6	4
133	Initial extended resection or neoadjuvant therapy for T4 non-small cell lung cancer—what is the evidence?. Shanghai Chest, 2018, 2, 76-76.	0.3	4
134	Perioperative mortality and morbidity after sublobar versus lobar resection for early-stage non-small-cell lung cancer: post-hoc analysis of an international, randomised, phase 3 trial (CALGB/Alliance 140503). Lancet Respiratory Medicine,the, 2018, 6, 915-924.	5.2	268
135	Asynchronous optical sampling data-acquisition trigger-signal derived from pulse coherence coincidence. Review of Scientific Instruments, 2018, 89, 113108.	0.6	5
136	Neutrophil to Lymphocyte Ratio as Predictor of Treatment Response in Esophageal Squamous Cell Cancer. Annals of Thoracic Surgery, 2018, 106, 864-871.	0.7	26
137	Postoperative Radiotherapy for Surgically Resected ypN2 Non-Small Cell LungÂCancer. Annals of Thoracic Surgery, 2018, 106, 848-855.	0.7	17
138	Clinical outcomes of patients with resected, early-stage ALK-positive lung cancer. Lung Cancer, 2018, 122, 67-71.	0.9	35
139	Histologic subtyping in pathologic stage I-IIA lung adenocarcinoma provides risk-based stratification for surveillance. Oncotarget, 2018, 9, 35742-35751.	0.8	24
140	Trans sodium crocetinate with temozolomide and radiation therapy for glioblastoma multiforme. Journal of Neurosurgery, 2017, 126, 460-466.	0.9	31
141	Long-term Survival Based on the Surgical Approach to Lobectomy For Clinical Stage I Nonsmall Cell Lung Cancer. Annals of Surgery, 2017, 265, 431-437.	2.1	248
142	Early operative outcomes and learning curve of robotic assisted giant paraesophageal hernia repair. International Journal of Medical Robotics and Computer Assisted Surgery, 2017, 13, e1730.	1.2	22
143	The American Association for Thoracic Surgery consensus guidelines for the management of empyema. Journal of Thoracic and Cardiovascular Surgery, 2017, 153, e129-e146.	0.4	232
144	Prospective study of giant paraesophageal hernia repair with 1-year follow-up. Journal of Thoracic and Cardiovascular Surgery, 2017, 154, 743-751.	0.4	18

#	Article	IF	CITATIONS
145	Adjuvant Chemotherapy Is Associated With Improved Survival in Locally Invasive Node Negative Non-Small Cell Lung Cancer. Annals of Thoracic Surgery, 2017, 104, 303-307.	0.7	15
146	Pulmonary metastasectomy with therapeutic intent for soft-tissue sarcoma. Journal of Thoracic and Cardiovascular Surgery, 2017, 154, 319-330.e1.	0.4	96
147	Defining quality in the surgical care of lung cancer patients. Journal of Thoracic and Cardiovascular Surgery, 2017, 154, 1397-1403.	0.4	15
148	Incidence of occult pN2 disease following resection and mediastinal lymph node dissection in clinical stage I lung cancer patients. European Journal of Cardio-thoracic Surgery, 2017, 51, 674-679.	0.6	74
149	Normal and Cancerous Tissues Release Extrachromosomal Circular DNA (eccDNA) into the Circulation. Molecular Cancer Research, 2017, 15, 1197-1205.	1.5	165
150	MA12.10 Histological Subtyping of Matched Primary and Metastases Sites in Lung Adenocarcinoma: Significance of Solid Predominance. Journal of Thoracic Oncology, 2017, 12, S414-S415.	0.5	1
151	Is Repeat Pulmonary Metastasectomy Indicated for Soft Tissue Sarcoma?. Annals of Thoracic Surgery, 2017, 104, 1837-1845.	0.7	28
152	The RNA-editing enzyme ADAR promotes lung adenocarcinoma migration and invasion by stabilizing <i>FAK</i> . Science Signaling, 2017, 10, .	1.6	52
153	Impact of Increasing Age on Cause-Specific Mortality and Morbidity in Patients With Stage I Non–Small-Cell Lung Cancer: A Competing Risks Analysis. Journal of Clinical Oncology, 2017, 35, 281-290.	0.8	170
154	Lung Adenocarcinoma: Predictive Value of <i>KRAS</i> Mutation Status in Assessing Local Recurrence in Patients Undergoing Image-guided Ablation. Radiology, 2017, 282, 251-258.	3.6	25
155	Liquid biopsy for ctDNA to revolutionize the care of patients with early stage lung cancers. Annals of Translational Medicine, 2017, 5, 479-479.	0.7	11
156	Editorial on: multidisciplinary therapy of marginally operable stage IIIA non-small cell lung cancer. Journal of Thoracic Disease, 2017, 9, 1826-1827.	0.6	1
157	Adjuvant chemotherapy for a T3 additional tumor nodule in the same lobe: ready for prime time?. Journal of Thoracic Disease, 2016, 8, E1709-E1710.	0.6	0
158	Detection of Recurrence Patterns After Wedge Resection for Early Stage Lung Cancer: Rationale for Radiologic Follow-Up. Annals of Thoracic Surgery, 2016, 102, 1067-1073.	0.7	12
159	KRAS Mutation Is a Significant Prognostic Factor in Early-stage Lung Adenocarcinoma. American Journal of Surgical Pathology, 2016, 40, 1579-1590.	2.1	50
160	Management of stage IIIA (N2) non-small-cell lung cancer: a transatlantic perspective. European Journal of Cardio-thoracic Surgery, 2016, 49, 1025-1027.	0.6	12
161	A career in translational research: The road not taken. Journal of Thoracic and Cardiovascular Surgery, 2016, 152, 367-368.	0.4	0
162	Postinduction positron emission tomography assessment of N2 nodes is not associated with ypN2 disease or overall survival in stage IIIA non–small cell lung cancer. Journal of Thoracic and Cardiovascular Surgery, 2016, 151, 969-979.e3.	0.4	23

#	Article	IF	CITATIONS
163	Timing of CSF-1/CSF-1R signaling blockade is critical to improving responses to CTLA-4 based immunotherapy. Oncolmmunology, 2016, 5, e1151595.	2.1	57
164	Determining the value of pulmonary metastasectomy. European Journal of Cardio-thoracic Surgery, 2016, 50, 800-800.	0.6	3
165	Surgical immune interventions for solid malignancies. American Journal of Surgery, 2016, 212, 682-690.e5.	0.9	9
166	Attaining Proficiency in Robotic-Assisted Minimally Invasive Esophagectomy While Maximizing Safety during Procedure Development. Innovations: Technology and Techniques in Cardiothoracic and Vascular Surgery, 2016, 11, 268-273.	0.4	63
167	A Nomogram to Predict Recurrence and Survival of High-Risk Patients Undergoing Sublobar Resection for Lung Cancer: An Analysis of a Multicenter Prospective Study (ACOSOG Z4032). Annals of Thoracic Surgery, 2016, 102, 239-246.	0.7	36
168	Impact of Sublobar Resection on Pulmonary Function: Long-Term Results from American College of Surgeons Oncology Group Z4032 (Alliance). Annals of Thoracic Surgery, 2016, 102, 230-238.	0.7	18
169	CK2α' Drives Lung Cancer Metastasis by Targeting BRMS1 Nuclear Export and Degradation. Cancer Research, 2016, 76, 2675-2686.	0.4	26
170	Management of Stage IIIA (N2) Non-Small Cell Lung Cancer: A Transatlantic Perspective. Annals of Thoracic Surgery, 2016, 101, 1247-1250.	0.7	11
171	Management of stage IIIA (N2) non–small cell lung cancer: A transatlantic perspective. Journal of Thoracic and Cardiovascular Surgery, 2016, 151, 1235-1238.	0.4	34
172	The American Association for Thoracic Surgery Consensus Guidelines: Reasons and purpose. Journal of Thoracic and Cardiovascular Surgery, 2016, 151, 935-939.e1.	0.4	15
173	Preoperative Chemoprophylaxis Is Safe in Major Oncology Operations and Effective at Preventing Venous Thromboembolism. Journal of the American College of Surgeons, 2016, 222, 129-137.	0.2	34
174	Pretreatment Dysphagia in Esophageal Cancer Patients May Eliminate the Need for Staging by Endoscopic Ultrasonography. Annals of Thoracic Surgery, 2016, 101, 226-230.	0.7	31
175	Immunotherapy for non-small cell lung cancer: current concepts and clinical trials. European Journal of Cardio-thoracic Surgery, 2016, 49, 1324-1333.	0.6	33
176	International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society classification predicts occult lymph node metastasis in clinically mediastinal node-negative lung adenocarcinoma. European Journal of Cardio-thoracic Surgery, 2016, 49, e9-e15.	0.6	64
177	Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition. Journal of Clinical Investigation, 2016, 126, 3130-3144.	3.9	773
178	Cell cycle progression score is a marker for five-year lung cancer-specific mortality risk in patients with resected stage I lung adenocarcinoma. Oncotarget, 2016, 7, 35241-35256.	0.8	17
179	Tumor Budding Correlates With the Protumor Immune Microenvironment and Is an Independent Prognostic Factor for Recurrence of Stage I Lung Adenocarcinoma. Chest, 2015, 148, 711-721.	0.4	53
180	Prognostic Impact of Immune Microenvironment in Lung Squamous Cell Carcinoma. Journal of Thoracic Oncology, 2015, 10, 1301-1310.	0.5	47

#	Article	IF	CITATIONS
181	Tumor Spread through Air Spaces is an Important Pattern of Invasion and Impacts the Frequency and Location of Recurrences after Limited Resection for Small Stage I Lung Adenocarcinomas. Journal of Thoracic Oncology, 2015, 10, 806-814.	0.5	428
182	Reevaluation and Reclassification of Resected Lung Carcinomas Originally Diagnosed as Squamous Cell Carcinoma Using Immunohistochemical Analysis. American Journal of Surgical Pathology, 2015, 39, 1170-1180.	2.1	61
183	Chylothorax and Recurrent Laryngeal Nerve Injury Associated with Robotic Video-Assisted Mediastinal Lymph Node Dissection. Innovations: Technology and Techniques in Cardiothoracic and Vascular Surgery, 2015, 10, 170-173.	0.4	12
184	Small RNA Sequencing for Profiling MicroRNAs in Long-Term Preserved Formalin-Fixed and Paraffin-Embedded Non-Small Cell Lung Cancer Tumor Specimens. PLoS ONE, 2015, 10, e0121521.	1.1	19
185	Sternal Resections: Conventional and Novel Materials for Reconstruction. Current Surgery Reports, 2015, 3, 1.	0.4	0
186	Activin Upregulation by NF-κB Is Required to Maintain Mesenchymal Features of Cancer Stem–like Cells in Non–Small Cell Lung Cancer. Cancer Research, 2015, 75, 426-435.	0.4	73
187	Analysis of longitudinal quality-of-life data in high-risk operable patients with lung cancer: Results from the ACOSOG Z4032 (Alliance) multicenter randomized trial. Journal of Thoracic and Cardiovascular Surgery, 2015, 149, 718-726.	0.4	59
188	Esophageal adenocarcinoma: Wanted—new models and better targets. Journal of Thoracic and Cardiovascular Surgery, 2015, 150, 288.	0.4	0
189	Tumoral CD10 expression correlates with high-grade histology and increases risk of recurrence in patients with stage I lung adenocarcinoma. Lung Cancer, 2015, 89, 329-336.	0.9	11
190	Comparing surgical infections in National Surgical Quality Improvement Project and an Institutional Database. Journal of Surgical Research, 2015, 196, 416-420.	0.8	15
191	Results of the National Lung Cancer Screening Trial. Thoracic Surgery Clinics, 2015, 25, 145-153.	0.4	25
192	Tumoral CD10 Expression Correlates with Aggressive Histology and Prognosis in Patients with Malignant Pleural Mesothelioma. Annals of Surgical Oncology, 2015, 22, 3136-3143.	0.7	9
193	Solid Predominant Histologic Subtype in Resected Stage I Lung Adenocarcinoma Is an Independent Predictor of Early, Extrathoracic, Multisite Recurrence and of Poor Postrecurrence Survival. Journal of Clinical Oncology, 2015, 33, 2877-2884.	0.8	181
194	The tumoral and stromal immune microenvironment in malignant pleural mesothelioma: A comprehensive analysis reveals prognostic immune markers. Oncolmmunology, 2015, 4, e1009285.	2.1	112
195	Chest Wall Reconstruction Using a Methyl Methacrylate Neo-Rib and Mesh. Annals of Thoracic Surgery, 2015, 100, 744-747.	0.7	20
196	Resection of Primary and Secondary Tumors of the Sternum: An Analysis of Prognostic Variables. Annals of Thoracic Surgery, 2015, 100, 215-222.	0.7	15
197	Do we know bad science when we see it?. Journal of Thoracic and Cardiovascular Surgery, 2015, 150, 472-473.	0.4	9
198	Thymic carcinoma outcomes and prognosis: Results of an international analysis. Journal of Thoracic and Cardiovascular Surgery, 2015, 149, 95-101.e2.	0.4	190

#	Article	IF	CITATIONS
199	Where have all the clinical trials gone?. Journal of Thoracic and Cardiovascular Surgery, 2015, 149, 5-6.	0.4	9
200	Utility of mediastinoscopy in clinical stage I lung cancers at risk for occult mediastinal nodal metastases. Journal of Thoracic and Cardiovascular Surgery, 2015, 149, 35-42.e1.	0.4	29
201	Loss of BRMS1 Promotes a Mesenchymal Phenotype through NF-κB-Dependent Regulation of <i>Twist1</i> . Molecular and Cellular Biology, 2015, 35, 303-317.	1.1	41
202	Nuclear estrogen receptor-α expression is an independent predictor of recurrence in male patients with pT1aN0 lung adenocarcinomas, and correlates with regulatory T-cell infiltration. Oncotarget, 2015, 6, 27505-27518.	0.8	21
203	Chylothorax and Recurrent Laryngeal Nerve Injury Associated with Robotic Video-Assisted Mediastinal Lymph Node Dissection. Innovations: Technology and Techniques in Cardiothoracic and Vascular Surgery, 2015, 10, 170-173.	0.4	0
204	Inhibition of Breast Cancer Metastasis Suppressor 1 Promotes a Mesenchymal Phenotype in Lung Epithelial Cells That Express Oncogenic K-RasV12 and Loss of p53. PLoS ONE, 2014, 9, e95869.	1.1	9
205	Predictors of Hospital Discharge to an Extended Care Facility after Major General Thoracic Surgery. American Surgeon, 2014, 80, 284-289.	0.4	8
206	Recent advances and clinical implications of the micropapillary histological subtype in lung adenocarcinomas. Lung Cancer Management, 2014, 3, 245-253.	1.5	12
207	The New IASLC-ATS-ERS Lung Adenocarcinoma Classification: What the Surgeon Should Know. Seminars in Thoracic and Cardiovascular Surgery, 2014, 26, 210-222.	0.4	76
208	Regional delivery of mesothelin-targeted CAR T cell therapy generates potent and long-lasting CD4-dependent tumor immunity. Science Translational Medicine, 2014, 6, 261ra151.	5.8	432
209	Intraoperative Near-Infrared Fluorescence Imaging as an Adjunct to Robotic-Assisted Minimally Invasive Esophagectomy. Innovations: Technology and Techniques in Cardiothoracic and Vascular Surgery, 2014, 9, 391-393.	0.4	54
210	The tumor immune microenvironment in octogenarians with stage I non-small cell lung cancer. Oncolmmunology, 2014, 3, e967142.	2.1	5
211	Thirty-Day Mortality Underestimates the Risk of Early Death After Major Resections for Thoracic Malignancies. Annals of Thoracic Surgery, 2014, 98, 1769-1775.	0.7	68
212	Differences in Patterns of Recurrence in Early-Stage Versus Locally Advanced Non-Small Cell LungÂCancer. Annals of Thoracic Surgery, 2014, 98, 1755-1761.	0.7	79
213	Impact of Brachytherapy on Local Recurrence Rates After Sublobar Resection: Results From ACOSOG Z4032 (Alliance), a Phase III Randomized Trial for High-Risk Operable Non–Small-Cell Lung Cancer. Journal of Clinical Oncology, 2014, 32, 2456-2462.	0.8	97
214	Comprehensive Long-Term Care of Patients With Lung Cancer: Development of a Novel Thoracic Survivorship Program. Annals of Thoracic Surgery, 2014, 98, 955-961.	0.7	21
215	Second Primary Lung Cancers: Smokers Versus Nonsmokers After Resection of Stage I Lung Adenocarcinoma. Annals of Thoracic Surgery, 2014, 98, 968-974.	0.7	44
216	Predictors of Early Recurrence for Node-Negative T1 to T2b Non-Small Cell Lung Cancer. Annals of Thoracic Surgery, 2014, 98, 1175-1183.	0.7	39

#	Article	IF	CITATIONS
217	Accuracy of Fluorodeoxyglucose-Positron Emission Tomography Within the Clinical Practice of the American College of Surgeons Oncology Group Z4031 Trial to Diagnose Clinical Stage I Non-Small Cell Lung Cancer. Annals of Thoracic Surgery, 2014, 97, 1142-1148.	0.7	38
218	Marginal pulmonary function should not preclude lobectomy inÂselected patients with non–small cell lung cancer. Journal of Thoracic and Cardiovascular Surgery, 2014, 147, 738-746.	0.4	38
219	FDG Positron Emission Tomography and Computed Tomography Demonstration of Carcinoma Arising in an Epiphrenic Diverticulum. Journal of Radiology Case Reports, 2014, 8, 42-46.	0.2	2
220	Intraoperative Near-Infrared Fluorescence Imaging as an Adjunct to Robotic-Assisted Minimally Invasive Esophagectomy. Innovations: Technology and Techniques in Cardiothoracic and Vascular Surgery, 2014, 9, 391-393.	0.4	1
221	Validation of the new IASLC/ATS/ERS lung adenocarcinoma classification: a surgeon's perspective. Journal of Thoracic Disease, 2014, 6, S547-51.	0.6	3
222	Implementing the new IASLC/ATS/ERS classification of lung adenocarcinomas: results from international and Chinese cohorts. Journal of Thoracic Disease, 2014, 6, S568-80.	0.6	10
223	Comment on He et al., VATS bronchial sleeve resection. Journal of Thoracic Disease, 2014, 6, 1376-7.	0.6	1
224	Leiomyoma Presenting asÂa Massive Calcified Circumferential Esophageal Mass. Annals of Thoracic Surgery, 2013, 96, 1851-1854.	0.7	5
225	Segmentectomy Versus Wedge Resection for Non-Small Cell Lung Cancer in High-Risk Operable Patients. Annals of Thoracic Surgery, 2013, 96, 1747-1755.	0.7	106
226	Minimally Invasive Ivor Lewis Esophagectomy. Operative Techniques in Thoracic and Cardiovascular Surgery, 2013, 18, 254-263.	0.2	1
227	Lymph Node Ratio Predicts Recurrence and Survival After RO Resection for Non-Small Cell Lung Cancer. Annals of Thoracic Surgery, 2013, 96, 1163-1170.	0.7	44
228	Epigenetic coordination of signaling pathways during the epithelial-mesenchymal transition. Epigenetics and Chromatin, 2013, 6, 28.	1.8	42
229	Pulmonary resections performed at hospitals with thoracic surgery residency programs have superior outcomes. Journal of Thoracic and Cardiovascular Surgery, 2013, 145, 60-67.e2.	0.4	20
230	Ten-Year Experience on 644 Patients Undergoing Single-Port (Uniportal) Video-Assisted Thoracoscopic Surgery. Annals of Thoracic Surgery, 2013, 96, 434-438.	0.7	169
231	Influence of hemodialysis on clinical outcomes after lung transplantation. Journal of Surgical Research, 2013, 183, 916-921.	0.8	14
232	Reply. Annals of Thoracic Surgery, 2013, 96, 744-745.	0.7	0
233	Long-Term Satisfaction and Medication Dependence After Antireflux Surgery. Annals of Thoracic Surgery, 2013, 96, 1246-1251.	0.7	6
234	Induction Chemoradiotherapy and Surgery forÂEsophageal Cancer: Survival Benefit WithÂDownstaging. Annals of Thoracic Surgery, 2013, 96, 225-231.	0.7	12

#	Article	IF	CITATIONS
235	Special Treatment Issues in Non-small Cell Lung Cancer. Chest, 2013, 143, e369S-e399S.	0.4	305
236	BRMS1 Suppresses Lung Cancer Metastases through an E3 Ligase Function on Histone Acetyltransferase p300. Cancer Research, 2013, 73, 1308-1317.	0.4	38
237	NF-κB Regulates Mesenchymal Transition for the Induction of Non-Small Cell Lung Cancer Initiating Cells. PLoS ONE, 2013, 8, e68597.	1.1	95
238	Integrated Therapeutic Approaches in the Treatment of Locally Advanced Non-small Cell Lung Cancer. Anti-Cancer Agents in Medicinal Chemistry, 2013, 13, 844-851.	0.9	3
239	Teaching video-assisted thoracic surgery (VATS) lobectomy. Journal of Thoracic Disease, 2013, 5 Suppl 3, S207-11.	0.6	14
240	Factors impacting oncologic outcomes after sublobar pulmonary resection: Results from ACOSOG Z4032 (Alliance), a randomized trial for high-risk operable non-small cell lung cancer (NSCLC) Journal of Clinical Oncology, 2013, 31, 7524-7524.	0.8	0
241	S-Nitrosoglutathione Reductase in Human Lung Cancer. American Journal of Respiratory Cell and Molecular Biology, 2012, 46, 63-70.	1.4	32
242	Hospital Procedure Volume Should Not Be Used as a Measure of Surgical Quality. Annals of Surgery, 2012, 256, 606-615.	2.1	85
243	Phase I Trial of Induction Histone Deacetylase and Proteasome Inhibition Followed by Surgery in Non–Small-Cell Lung Cancer. Journal of Thoracic Oncology, 2012, 7, 1683-1690.	0.5	46
244	Pathologic Lymph Node Ratio Is a Predictor of Survival in Esophageal Cancer. Annals of Thoracic Surgery, 2012, 94, 1643-1651.	0.7	38
245	Invited Commentary. Annals of Thoracic Surgery, 2012, 94, 1847.	0.7	0
246	Invited Commentary. Annals of Thoracic Surgery, 2012, 94, 1679.	0.7	0
247	Differences in reported esophageal cancer resection outcomes between national clinical and administrative databases. Journal of Thoracic and Cardiovascular Surgery, 2012, 144, 1152-1159.	0.4	55
248	Modification of RelA by O <i>-</i> linked <i>N</i> -acetylglucosamine links glucose metabolism to NF-κB acetylation and transcription. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 16888-16893.	3.3	88
249	Survival after lung transplant for coal workers' pneumoconiosis. Journal of Heart and Lung Transplantation, 2012, 31, 1315-1318.	0.3	14
250	A Diagnostic Consideration for All Ages: Pseudoachalasia in a 22-Year-Old Male. Annals of Thoracic Surgery, 2012, 93, e11-e12.	0.7	5
251	Tumor Recurrence After Complete Resection for Non-Small Cell Lung Cancer. Annals of Thoracic Surgery, 2012, 93, 1813-1821.	0.7	142
252	The Society of Thoracic Surgeons General Thoracic Surgery Database: Establishing Generalizability to National Lung Cancer Resection Outcomes. Annals of Thoracic Surgery, 2012, 94, 216-221.	0.7	68

#	Article	IF	CITATIONS
253	Invited Commentary. Annals of Thoracic Surgery, 2012, 94, 225.	0.7	Ο
254	Accuracy of FDG-PET to diagnose lung cancer in the ACOSOG Z4031 trial Journal of Clinical Oncology, 2012, 30, 7008-7008.	0.8	3
255	Number of Lymph Nodes Harvested From a Mediastinal Lymphadenectomy. Chest, 2011, 139, 1124-1129.	0.4	116
256	The impact of adjuvant brachytherapy with sublobar resection on pulmonary function and dyspnea in high-risk patients with operable disease: Preliminary results from the American College of Surgeons Oncology Group Z4032 Trial. Journal of Thoracic and Cardiovascular Surgery, 2011, 142, 554-562.	0.4	39
257	Randomized trial of mediastinal lymph node sampling versus complete lymphadenectomy during pulmonary resection in the patient with N0 or N1 (less than hilar) non–small cell carcinoma: Results of the American College of Surgery Oncology Group Z0030 Trial. Journal of Thoracic and Cardiovascular Surgery. 2011. 141. 662-670.	0.4	660
258	Bronchiolitis obliterans syndrome occurs earlier in the post–lung allocation score era. Journal of Thoracic and Cardiovascular Surgery, 2011, 141, 1278-1282.	0.4	3
259	A positive return on investment: Research funding by the Thoracic Surgery Foundation for Research and Education (TSFRE). Journal of Thoracic and Cardiovascular Surgery, 2011, 141, 1103-1106.	0.4	25
260	Thirty- and ninety-day outcomes after sublobar resection with and without brachytherapy for non–small cell lung cancer: Results from a multicenter phase III study. Journal of Thoracic and Cardiovascular Surgery, 2011, 142, 1143-1151.	0.4	73
261	Parenchymal-Sparing Lung Resections: Technique of Sleeve Resections. Operative Techniques in Thoracic and Cardiovascular Surgery, 2011, 16, 215-225.	0.2	Ο
262	Existing General Population Models Inaccurately Predict Lung Cancer Risk in Patients Referred for Surgical Evaluation. Annals of Thoracic Surgery, 2011, 91, 227-233.	0.7	52
263	Gender, Race, and Socioeconomic Status Affects Outcomes After Lung Cancer Resections in the United States. Annals of Thoracic Surgery, 2011, 92, 434-439.	0.7	64
264	Characterization of Novel Synthesized Small Molecular Compounds Against Non-Small Cell Lung Cancer. Annals of Thoracic Surgery, 2011, 92, 1031-1037.	0.7	4
265	Intraoperative Factors and the Risk of Respiratory Complications After Pneumonectomy. Annals of Thoracic Surgery, 2011, 92, 1188-1194.	0.7	26
266	Geographic Distance Between Donor and Recipient Does Not Influence Outcomes After Lung Transplantation. Annals of Thoracic Surgery, 2011, 92, 1847-1853.	0.7	20
267	Seasonal variation influences outcomes following lung cancer resections. European Journal of Cardio-thoracic Surgery, 2011, 40, 83-90.	0.6	18
268	Occult Metastases in Lymph Nodes Predict Survival in Resectable Non–Small-Cell Lung Cancer: Report of the ACOSOG Z0040 Trial. Journal of Clinical Oncology, 2011, 29, 4313-4319.	0.8	96
269	Bilateral Pulmonary Sequestration. American Journal of Respiratory and Critical Care Medicine, 2011, 184, 141-141.	2.5	2
270	Depletion of tissue plasminogen activator attenuates lung ischemia-reperfusion injury via inhibition of neutrophil extravasation. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2011, 300, L718-L729.	1.3	24

#	Article	IF	CITATIONS
271	Primary Payer Status Affects Mortality for Major Surgical Operations. Annals of Surgery, 2010, 252, 544-551.	2.1	239
272	Phase I Trial of Intrapleural Docetaxel Administered Through an Implantable Catheter in Subjects with a Malignant Pleural Effusion. Journal of Thoracic Oncology, 2010, 5, 75-81.	0.5	42
273	Video-assisted thoracic surgery versus open lobectomy for lung cancer: A secondary analysis of data from the American College of Surgeons Oncology Group Z0030 randomized clinical trial. Journal of Thoracic and Cardiovascular Surgery, 2010, 139, 976-983.	0.4	328
274	Combined proteasome and histone deacetylase inhibition attenuates epithelial–mesenchymal transition through E-cadherin in esophageal cancer cells. Journal of Thoracic and Cardiovascular Surgery, 2010, 139, 1224-1232.e1.	0.4	17
275	Size matters: A comparison of T1 and T2 peripheral non–small-cell lung cancers treated with stereotactic body radiation therapy (SBRT). Journal of Thoracic and Cardiovascular Surgery, 2010, 140, 583-589.	0.4	120
276	Transplant Pneumonectomy in a Patient With an Acutely Thrombosed Allograft. Annals of Thoracic Surgery, 2010, 89, 975-977.	0.7	0
277	The Legends Behind Cardiothoracic Surgical Instruments. Annals of Thoracic Surgery, 2010, 89, 1693-1700.	0.7	9
278	A Thoracic Surgeon–Directed Tobacco Cessation Intervention. Annals of Thoracic Surgery, 2010, 89, 926-930.	0.7	16
279	Donor Factors Are Associated With Bronchiolitis Obliterans Syndrome After Lung Transplantation. Annals of Thoracic Surgery, 2010, 89, 1555-1562.	0.7	36
280	Donor Age Is Associated With Chronic Allograft Vasculopathy After Adult Heart Transplantation: Implications for Donor Allocation. Annals of Thoracic Surgery, 2010, 90, 168-175.	0.7	83
281	STS Database Risk Models: Predictors of Mortality and Major Morbidity for Lung Cancer Resection. Annals of Thoracic Surgery, 2010, 90, 875-883.	0.7	303
282	Helical Tomotherapy-Based STAT Stereotactic Body Radiation Therapy: Dosimetric Evaluation for a Real-Time SBRT Treatment Planning and Delivery Program. Medical Dosimetry, 2010, 35, 312-319.	0.4	12
283	<i>BRMS1</i> transcriptional repression correlates with CpG island methylation and advanced pathological stage in nonâ€small cell lung cancer. Journal of Pathology, 2010, 221, 229-237.	2.1	38
284	Multigene Expression–Based Predictors for Sensitivity to Vorinostat and Velcade in Non–Small Cell Lung Cancer. Molecular Cancer Therapeutics, 2010, 9, 2834-2843.	1.9	20
285	Esophageal inflammatory myofibroblastic tumor sampled by EUS-FNA. Gastrointestinal Endoscopy, 2010, 72, 209-210.	0.5	5
286	Rosai-Dorfman Disease Presenting as a Pulmonary Artery Mass. Annals of Thoracic Surgery, 2010, 89, 300-302.	0.7	15
287	Correlations between selected tumor markers and fluorodeoxyglucose maximal standardized uptake values in esophageal cancerâ [~] †. European Journal of Cardio-thoracic Surgery, 2009, 35, 699-705.	0.6	22
288	A bilobed thoracic outlet mass: Options for resection. Journal of Thoracic and Cardiovascular Surgery, 2009, 137, 245-247.	0.4	5

#	Article	IF	CITATIONS
289	Fluorodeoxyglucose positron emission tomography and tumor marker expression in non–small cell lung cancer. Journal of Thoracic and Cardiovascular Surgery, 2009, 137, 43-48.	0.4	33
290	Does reperfusion injury still cause significant mortality after lung transplantation?. Journal of Thoracic and Cardiovascular Surgery, 2009, 137, 688-694.	0.4	40
291	Predicted Risk of Mortality Models: Surgeons Need to Understand Limitations of the University HealthSystem Consortium Models. Journal of the American College of Surgeons, 2009, 209, 551-556.	0.2	36
292	Breast cancer metastasis suppressor 1 (BRMS1) suppresses metastasis and correlates with improved patient survival in non-small cell lung cancer. Cancer Letters, 2009, 276, 196-203.	3.2	75
293	Genetic Markers of Mediastinal Tumors. Thoracic Surgery Clinics, 2009, 19, 17-27.	0.4	4
294	Preoperative Embolization of Castleman's Disease Using Microspheres. Annals of Thoracic Surgery, 2009, 88, 1999-2001.	0.7	10
295	Basaloid Squamous Cell Carcinoma of the Esophagus: Assessment for High-risk Human Papillomavirus and Related Molecular Markers. American Journal of Surgical Pathology, 2009, 33, 1608-1614.	2.1	45
296	Endoscopic Ultrasound-guided Fine Needle Aspiration of a Malignant Pleural Effusion to Diagnose and Stage Lung Cancer: When Should this Approach be Considered?. Digestive Diseases and Sciences, 2008, 53, 757-759.	1.1	1
297	Reproducibility of Interfraction Lung Motion Probability Distribution Function Using Dynamic MRI: Statistical Analysis. International Journal of Radiation Oncology Biology Physics, 2008, 72, 1228-1235.	0.4	36
298	Technique of Superior Vena Cava Resection for Lung Carcinomas. Operative Techniques in Thoracic and Cardiovascular Surgery, 2008, 13, 274-282.	0.2	5
299	The impact of the lung allocation score on short-term transplantation outcomes: A multicenter study. Journal of Thoracic and Cardiovascular Surgery, 2008, 135, 166-171.	0.4	136
300	Effects of induction immunosuppression regimen on acute rejection, bronchiolitis obliterans, and survival after lung transplantation. Journal of Thoracic and Cardiovascular Surgery, 2008, 135, 594-602.	0.4	42
301	Identification of Small Lung Nodules: Technique of Radiotracer-Guided Thoracoscopic Biopsy. Annals of Thoracic Surgery, 2008, 85, S772-S777.	0.7	72
302	Does Positron Emission Tomography Prevent Nontherapeutic Pulmonary Resections for Clinical Stage IA Lung Cancer?. Annals of Thoracic Surgery, 2008, 85, 1166-1170.	0.7	44
303	Radiotracer-Guided Thoracoscopic Resection is a Cost-Effective Technique for the Evaluation of Subcentimeter Pulmonary Nodules. Annals of Thoracic Surgery, 2008, 86, 934-940.	0.7	20
304	Measuring the Quality of Surgical Outcomes in General Thoracic Surgery: Should Surgical Volume Be Used to Direct Patient Referrals?. Annals of Thoracic Surgery, 2008, 86, 1405-1408.	0.7	25
305	VATS Lobectomy is Better than Open Thoracotomy: What is the Evidence for Short-Term Outcomes?. Thoracic Surgery Clinics, 2008, 18, 249-258.	0.4	73
306	Does FDG-PET Add Information to EUS and CT in the Initial Management of Esophageal Cancer? A Prospective Single Center Study. American Journal of Gastroenterology, 2008, 103, 570-574.	0.2	26

#	Article	IF	CITATIONS
307	Quality of life following primary vs. redo transthoracic paraesophageal hernia repairs. Interactive Cardiovascular and Thoracic Surgery, 2008, 7, 71-74.	0.5	6
308	BIOLOGY AND EPIDEMIOLOGY OF LUNG CANCER. , 2008, , 708-728.		2
309	Special Treatment Issues in Lung Cancer. Chest, 2007, 132, 290S-305S.	0.4	219
310	EUS-FNA as the Initial Diagnostic Modality in Centrally Located Primary Lung Cancers. Journal of Clinical Gastroenterology, 2007, 41, 657-660.	1.1	31
311	Obesity Does Not Increase Complications After Anatomic Resection for Non-Small Cell Lung Cancer. Annals of Thoracic Surgery, 2007, 84, 1098-1106.	0.7	58
312	Functional Interdependence at the Chromatin Level between the MKK6/p38 and IGF1/PI3K/AKT Pathways during Muscle Differentiation. Molecular Cell, 2007, 28, 200-213.	4.5	174
313	Dose as a Function of Lung Volume and Planned Treatment Volume in Helical Tomotherapy Intensity-Modulated Radiation Therapy-Based Stereotactic Body Radiation Therapy for Small Lung Tumors. International Journal of Radiation Oncology Biology Physics, 2007, 68, 1229-1237.	0.4	36
314	Esophageal leiomyosarcoma diagnosed by endoscopic ultrasound-guided fine-needle aspiration. Diagnostic Cytopathology, 2007, 35, 167-170.	0.5	30
315	Novel Targeted Therapies for Non–Small Cell Lung Cancer. Thoracic Surgery Clinics, 2006, 16, 353-366.	0.4	1
316	Morbidity and Mortality of Major Pulmonary Resections in Patients With Early-Stage Lung Cancer: Initial Results of the Randomized, Prospective ACOSOG Z0030 Trial. Annals of Thoracic Surgery, 2006, 81, 1013-1020.	0.7	619
317	Stage IB Nonsmall Cell Lung Cancers: Are They All the Same?. Annals of Thoracic Surgery, 2006, 81, 1958-1962.	0.7	50
318	Economic Assessment of the General Thoracic Surgery Outpatient Service. Annals of Thoracic Surgery, 2006, 82, 1068-1071.	0.7	5
319	Clinical Experience With Radiotracer-Guided Thoracoscopic Biopsy of Small, Indeterminate Lung Nodules. Annals of Thoracic Surgery, 2006, 82, 1191-1197.	0.7	55
320	Lung Transplantation in Patients 60 Years and Older: Results, Complications, and Outcomes. Annals of Thoracic Surgery, 2006, 82, 1835-1841.	0.7	32
321	Invited commentary. Annals of Thoracic Surgery, 2006, 82, 2023.	0.7	0
322	Combined bronchial sleeve resection and repair of partial anomalous pulmonary venous return. Journal of Thoracic and Cardiovascular Surgery, 2006, 132, 982-983.	0.4	7
323	Endogenous S-Nitrosoglutathione Modifies 5-Lipoxygenase Expression in Airway Epithelial Cells. American Journal of Respiratory Cell and Molecular Biology, 2006, 34, 387-393.	1.4	35
324	Breast Cancer Metastasis Suppressor 1 Functions as a Corepressor by Enhancing Histone Deacetylase 1-Mediated Deacetylation of RelA/p65 and Promoting Apoptosis. Molecular and Cellular Biology, 2006, 26, 8683-8696.	1.1	113

#	Article	IF	CITATIONS
325	Suberoylanilide Hydroxamic Acid Induces Akt-mediated Phosphorylation of p300, Which Promotes Acetylation and Transcriptional Activation of RelA/p65. Journal of Biological Chemistry, 2006, 281, 31359-31368.	1.6	75
326	Suberoylanilide Hydroxamic Acid Induces Akt-mediated Phosphorylation of p300, Which Promotes Acetylation and Transcriptional Activation of RelA/p65. Journal of Biological Chemistry, 2006, 281, 31359-31368.	1.6	24
327	Laparoscopic Gastric Bypass Complicated by Gastric Pouch Necrosis: Considerations in Gastroesophageal Reconstruction. Journal of Gastrointestinal Surgery, 2005, 9, 938-940.	0.9	4
328	Suberoylanilide hydroxamic acid combined with gemcitabine enhances apoptosis in non–small cell lung cancer. Surgery, 2005, 138, 360-367.	1.0	41
329	Inhibition of phosphatidylinositol 3-kinase/Akt and histone deacetylase activity induces apoptosis in non–small cell lung cancer in vitro and in vivo. Journal of Thoracic and Cardiovascular Surgery, 2005, 130, 1422-1429.	0.4	32
330	Modulation of NF-κB-dependent transcription and cell survival by the SIRT1 deacetylase. EMBO Journal, 2004, 23, 2369-2380.	3.5	2,413
331	Combined histone deacetylase and NF-κB inhibition sensitizes non-small cell lung cancer to cell death. Surgery, 2004, 136, 416-425.	1.0	64
332	Proteasome inhibition sensitizes non–small cell lung cancer to histone deacetylase inhibitor–induced apoptosis through the generation of reactive oxygen species. Journal of Thoracic and Cardiovascular Surgery, 2004, 128, 740-748.	0.4	52
333	Combined proteasome and histone deacetylase inhibition in non–small cell lung cancer. Journal of Thoracic and Cardiovascular Surgery, 2004, 127, 1078-1086.	0.4	71
334	A novel technique for localization and excisional biopsy of small or Ill-defined pulmonary lesions. Annals of Thoracic Surgery, 2004, 77, 1756-1762.	0.7	50
335	Proteasome Inhibition Sensitizes Non–Small-Cell Lung Cancer to Gemcitabine-Induced Apoptosis. Annals of Thoracic Surgery, 2004, 78, 1207-1214.	0.7	104
336	Modulation of antiapoptotic cell signaling pathways in non-small cell lung cancer: the role of NF-κB. Seminars in Thoracic and Cardiovascular Surgery, 2004, 16, 28-39.	0.4	58
337	The molecular biology of lung cancer: introduction. Seminars in Thoracic and Cardiovascular Surgery, 2004, 16, 2.	0.4	1
338	P-338 Proteosome inhibition sensitizes NSCLC to generation of reactive oxygen species and cell death. Lung Cancer, 2003, 41, S177.	0.9	2
339	Pulmonary segmentectomy: results and complications. Annals of Thoracic Surgery, 2003, 76, 343-349.	0.7	58
340	Ineffectiveness of Histone Deacetylase Inhibitors to Induce Apoptosis Involves the Transcriptional Activation of NF-κB through the Akt Pathway. Journal of Biological Chemistry, 2003, 278, 18980-18989.	1.6	163
341	Special Treatment Issues*. Chest, 2003, 123, 244S-258S.	0.4	100
342	PTEN Blocks Tumor Necrosis Factor-induced NF-κB-dependent Transcription by Inhibiting the Transactivation Potential of the p65 Subunit. Journal of Biological Chemistry, 2002, 277, 11116-11125.	1.6	113

#	Article	IF	CITATIONS
343	Beneficial effects of inhaled nitric oxide in adult cardiac surgical patients. Annals of Thoracic Surgery, 2002, 73, 529-533.	0.7	33
344	lschemia-reperfusion injury after lung transplantation increases risk of late bronchiolitis obliterans syndrome. Annals of Thoracic Surgery, 2002, 73, 1041-1048.	0.7	240
345	Acquired systemic-to-pulmonary arteriovenous malformation secondary to Mycobacterium Tuberculosis empyema. Annals of Thoracic Surgery, 2002, 74, 1229-1231.	0.7	18
346	Coronary risk stratification in patients with end-stage lung disease. Journal of Heart and Lung Transplantation, 2002, 21, 334-339.	0.3	14
347	Inhibition of nuclear factor κB chemosensitizes non–small cell lung cancer through cytochrome c release and caspase activation. Journal of Thoracic and Cardiovascular Surgery, 2002, 123, 310-317.	0.4	56
348	Genetic differences between adenocarcinomas arising in Barrett's esophagus and gastric mucosa. Gastroenterology, 2001, 121, 592-598.	0.6	77
349	Influence of graft ischemic time on outcomes following lung transplantation. Journal of Heart and Lung Transplantation, 2001, 20, 1291-1296.	0.3	65
350	Chemotherapy-induced reactive oxygen species (ROS) activate NF-κB and are required to induce apoptosis following the loss of NF-IºB in NSCLC. Journal of the American College of Surgeons, 2000, 191, S64.	0.2	1
351	Inhibition of NF-κB sensitizes non–small cell lung cancer cells to chemotherapy-induced apoptosis. Annals of Thoracic Surgery, 2000, 70, 930-936.	0.7	109
352	Inadequacy of computed tomography in assessing patients with esophageal carcinoma after induction chemoradiotherapy. , 1999, 85, 1026-1032.		125
353	Reduced ischemia–reperfusion injury with rolipram in rat cadaver lung donors: effect of cyclic adenosine monophosphate. Annals of Thoracic Surgery, 1999, 67, 194-199.	0.7	22
354	Retrograde Arterial Bullet Embolus to the Coronary Artery. Arteriosclerosis, Thrombosis, and Vascular Biology, 1999, 46, 1135-1136.	1.1	6
355	Pancoast tumors of the lung. Current Opinion in Pulmonary Medicine, 1998, 4, 191-197.	1.2	13
356	Reduced Ischemia–Reperfusion Injury with Isoproterenol in Non-Heart-Beating Donor Lungs. Journal of Surgical Research, 1997, 69, 385-392.	0.8	17
357	Induction Chemoradiotherapy Followed by Esophagectomy in Patients With Carcinoma of the Esophagus. Annals of Thoracic Surgery, 1997, 64, 185-192.	0.7	73
358	Anatomically sound, simplified approach to repair of "complete―atrioventricular septal defect. Annals of Thoracic Surgery, 1997, 64, 487-494.	0.7	101
359	When does the lung die?K fc, cell viability, and adenine nucleotide changes in the circulation-arrested rat lung. Journal of Applied Physiology, 1997, 83, 247-252.	1.2	22
360	Selective lung ventilation during thoracoscopy: Effects of insufflation on hemodynamics. Annals of Thoracic Surgery, 1996, 61, 945-948.	0.7	52

#	Article	IF	CITATIONS
361	Biatrial approach to cardiac myxomas: A 30-year clinical experience. Annals of Thoracic Surgery, 1995, 59, 851-856.	0.7	84
362	A comprehensive curriculum for thoracic surgery: Survey of opinions from program directors and residents. Annals of Thoracic Surgery, 1995, 60, 877-887.	0.7	5
363	Use of microfibrillar collagen hemostat (Avitene) and thrombin to achieve hemostasis after median sternotomy. Journal of Thoracic and Cardiovascular Surgery, 1994, 108, 1151-1152.	0.4	6
364	Thoracoscopic Resection of Bilateral Metastatic Sarcomas Causing Spontaneous Pneumothorax. Chest, 1994, 106, 1274-1276.	0.4	5
365	Coronary-Subclavian Steal with Concomitant Carotid Disease: Indication for Axilloaxillary Bypass. Vascular Surgery, 1994, 28, 51-56.	0.3	1
366	Safe use of heparin-coated bypass circuits incorporating a pump-oxygenator. Annals of Thoracic Surgery, 1994, 57, 815-819.	0.7	20
367	Potential application of p53 as an intermediate biomarker in Barrett's esophagus. Annals of Thoracic Surgery, 1994, 57, 598-603.	0.7	52
368	Use of heparin-coated cardiopulmonary bypass. Annals of Thoracic Surgery, 1993, 56, 566-568.	0.7	21
369	The role of thoracoscopy in thoracic trauma. Annals of Thoracic Surgery, 1993, 56, 646-648.	0.7	37
370	Effects of insufflation on hemodynamics during thoracoscopy. Annals of Thoracic Surgery, 1993, 55, 1379-1382.	0.7	78
371	Unusual location of an atrial myxoma complicated by a secundum atrial septal defect. Annals of Thoracic Surgery, 1993, 55, 1252-1253.	0.7	12

Evaluation of solitary pulmonary nodule. , 0, , 115-120.

0